Grace Therapeutics, Inc.

NasdaqCM:GRCE Stock Report

Market Cap: US$33.3m

Grace Therapeutics Management

Management criteria checks 0/4

Grace Therapeutics' CEO is Prashant Kohli, appointed in Apr 2023, has a tenure of 1.58 years. total yearly compensation is $987.63K, comprised of 40.5% salary and 59.5% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $70.05K. The average tenure of the management team and the board of directors is 1.5 years and 1.4 years respectively.

Key information

Prashant Kohli

Chief executive officer

US$987.6k

Total compensation

CEO salary percentage40.5%
CEO tenure1.6yrs
CEO ownership0.2%
Management average tenure1.5yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Sep 02
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Apr 20
We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

Nov 14
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely?

We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

May 10
We're Not Very Worried About Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate

Acasti Pharma GAAP EPS of -$0.10

Aug 11

Acasti inks deal for Grace Therapeutics, shares surge

May 07

Acasti Pharma issues clarification on trading activity

Dec 23

Acasti Pharma EPS in-line

Nov 16

CEO Compensation Analysis

How has Prashant Kohli's remuneration changed compared to Grace Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024US$988kUS$400k

-US$13m

Dec 31 2023n/an/a

-US$39m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$42m

Mar 31 2023US$512kUS$379k

-US$42m

Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022US$655kUS$141k

-US$10m

Compensation vs Market: Prashant's total compensation ($USD987.63K) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Prashant's compensation has increased whilst the company is unprofitable.


CEO

Prashant Kohli (52 yo)

1.6yrs

Tenure

US$987,630

Compensation

Mr. Prashant Kohli was Vice President of Commercial Operations at Grace Therapeutics, Inc. He served as Chief Commercial Officer at Acasti Pharma Inc. since 2022 until April 04, 2023, and serves as its Chi...


Leadership Team

NamePositionTenureCompensationOwnership
Prashant Kohli
CEO & Director1.6yrsUS$987.63k0.21%
$ 70.0k
Amresh Kumar
VP of Program Management1.5yrsUS$405.75k0.11%
$ 36.5k
Carrie D'Andrea
VP of Clinical Operations1.5yrsUS$411.30k0%
$ 0
Robert DelAversano
VP of Finance and Principal Financial & Accounting Officerless than a yearno datano data
R. MacDonald
Member of Scientific Advisory Board & Chief Medical Officer1.5yrsno datano data

1.5yrs

Average Tenure

52yo

Average Age

Experienced Management: GRCE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Prashant Kohli
CEO & Director1.1yrsUS$987.63k0.21%
$ 70.0k
R. MacDonald
Member of Scientific Advisory Board & Chief Medical Officer2.5yrsno datano data
Edward Neugeboren
Independent Director1.1yrsUS$53.00k0.37%
$ 124.3k
A. Davis
Independent Director1.1yrsUS$57.50k0%
$ 0
Vimal Kavuru
Independent Chairman3.3yrsUS$127.43k15.92%
$ 5.3m
S. Kottayil
Director1.1yrsUS$44.90k3.65%
$ 1.2m
Andrew Ducruet
Member of Scientific Advisory Board2.5yrsno datano data
Alex Choi
Member of Scientific Advisory Board2.8yrsno datano data
W. Kimberly
Member of Scientific Advisory Board1.4yrsno datano data
Alejandro Rabinstein
Member of Scientific Advisory Board1.4yrsno datano data
Sherry Chou
Member of Scientific Advisory Board1.4yrsno datano data

1.4yrs

Average Tenure

56yo

Average Age

Experienced Board: GRCE's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.